Brief: Lipocine Announces Favorable Regulatory Pathway On Oral LPCN 1154

Lipocine

15/09/2022 13:46

Sept 15 (Reuters) - Lipocine Inc  LPCN.O :
    * LIPOCINE ANNOUNCES FAVORABLE REGULATORY PATHWAY ON ORAL
LPCN
1154 FOR POST-PARTUM DEPRESSION (PPD)
    * LIPOCINE INC - A PILOT PK BRIDGE STUDY IS PLANNED WITH
RESULTS
EXPECTED IN 1Q 2023
    * LIPOCINE - FDA AGREES WITH LIPOCINE ESTABLISHING LPCN 1154
PATHWAY TO EFFICACY THROUGH A PHARMACOKINETIC BRIDGE TO AN
APPROVED IV INFUSION BREXANOLONE
    * LIPOCINE INC - PLANS TO INITIATE A PILOT PK BRIDGE STUDY
OF LPCN
1154 AND AN FDA APPROVED IV INFUSION BREXANOLONE IN 4Q 2022

Source text for Eikon:  ID:nPn8kQWrga 
Further company coverage:  LPCN.O 

 ((Reuters.Briefs@thomsonreuters.com;))